VCNX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 51.50%

Insider Buying (Last 12 Months): $1,253,325.81

Insider Selling (Last 12 Months): $0.00

Vaccinex Insider Trading History Chart

Vaccinex Share Price & Price History

^$0.52

▼ -0.4764 (-47.64%)

As of 04/3/2025 01:23 PM ET

Days: 30 | 90 | 365

Vaccinex Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/9/2024	Albert Friedberg	Director	Buy	100	$4.51	$451.00	780,624
8/5/2024	Albert Friedberg	Director	Buy	3,653	$4.60	$16,803.80	777,771
7/31/2024	Albert Friedberg	Director	Buy	200,000	$6.15	$1,230,000.00	762,415
5/29/2024	Albert Friedberg	Director	Buy	957	$4.95	$4,737.15	561,554
4/19/2024	Albert Friedberg	Director	Buy	282	$4.73	$1,333.86	560,597
12/26/2023	Strydonck Gerald E. Van	Director	Sell	224	$10.08	$2,257.92
10/3/2023	Albert Friedberg	Director	Buy	214,285	$14.00	$2,999,990.00	339,128
10/3/2023	Maurice Zauderer	CEO	Buy	357	$13.02	$4,648.14	1,222

See Full Table

SEC Filings (Institutional Ownership Changes) for Vaccinex (NASDAQ:VCNX)

50.11% of Vaccinex stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Vaccinex Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/15/2024	Point72 Asset Management L.P.	166,000	$0.56M	0.0%	+42.4%	9.595%
8/15/2024	Armistice Capital LLC	94,000	$0.61M	0.0%	-35.2%	5.934%
8/7/2024	AIGH Capital Management LLC	108,958	$0.71M	0.2%	+86.7%	6.896%
2/12/2024	AIGH Capital Management LLC	817,061	$0.54M	0.2%	-25.1%	6.542%
2/9/2024	Worth Venture Partners LLC	654,079	$0.44M	0.2%	-8.8%	5.237%
11/15/2023	Worth Venture Partners LLC	717,559	$0.81M	0.5%	+417.0%	16.308%
11/15/2023	Armistice Capital LLC	680,000	$0.77M	0.0%	N/A	15.455%
11/13/2023	AIGH Capital Management LLC	1,090,173	$1.23M	0.6%	-19.4%	24.777%
5/15/2023	AIGH Capital Management LLC	951,801	$0.38M	0.1%	-61.2%	1.735%
5/1/2023	Virtu Financial LLC	103,898	$42K	0.0%	N/A	0.189%
2/16/2023	AIGH Capital Management LLC	2,451,801	$1.66M	0.5%	+17.8%	4.915%
5/12/2022	AIGH Capital Management LLC	2,081,801	$2.63M	0.6%	N/A	4.880%
11/16/2021	Telemetry Investments L.L.C.	132,500	$0.29M	0.4%	+10.4%	0.430%
11/15/2021	Natixis	31,895	$69K	0.0%	N/A	0.104%
11/12/2021	Oppenheimer & Co. Inc.	31,751	$69K	0.0%	-24.3%	0.103%
9/17/2021	Virtu Financial LLC	38,026	$0.11M	0.0%	+103.9%	0.123%
8/16/2021	Point72 Asset Management L.P.	395,522	$1.11M	0.0%	N/A	1.390%
8/16/2021	Telemetry Investments L.L.C.	120,000	$0.34M	0.5%	+14.3%	0.422%
8/16/2021	State Street Corp	67,200	$0.19M	0.0%	N/A	0.236%
8/13/2021	Geode Capital Management LLC	104,114	$0.29M	0.0%	+59.4%	0.366%
8/13/2021	Vanguard Group Inc.	600,624	$1.68M	0.0%	+145.9%	2.111%
5/19/2021	Virtu Financial LLC	18,652	$56K	0.0%	N/A	0.066%
5/17/2021	Goldman Sachs Group Inc.	20,447	$61K	0.0%	-41.9%	0.072%
5/13/2021	Bank of New York Mellon Corp	17,954	$54K	0.0%	N/A	0.063%
5/12/2021	Geode Capital Management LLC	65,331	$0.19M	0.0%	N/A	0.230%
5/12/2021	UBS Group AG	28,708	$86K	0.0%	N/A	0.101%
5/10/2021	Oppenheimer & Co. Inc.	42,951	$0.13M	0.0%	-24.3%	0.151%
5/4/2021	Institute for Wealth Management LLC.	20,000	$60K	0.0%	N/A	0.070%
2/16/2021	Squarepoint Ops LLC	40,583	$84K	0.0%	N/A	0.181%

Data available starting January 2016

See Full Table

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.

Today's Range

Now: $0.52

$0.52

$0.60

50 Day Range

MA: $0.95

$0.52

$1.29

52 Week Range

Now: $0.52

$0.28

$8.90

Volume

4,332 shs

Average Volume

57,399 shs

Market Capitalization

$1.36 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.1

Who are the company insiders with the largest holdings of Vaccinex?: Vaccinex's top insider investors include:
Albert Friedberg (Director)
Maurice Zauderer (CEO)
Strydonck Gerald E Van (Director)
Learn More about top insider investors at Vaccinex.